TCRT · Alaunos Therapeutics, Inc. · Financials
$1.49
-0.02 (-1.32%)
At close · Sep 14
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on the current cash forecast and the Company's dependence on its ability to obtain additional financing to fund its operations after the current resources are exhausted, about which there can be no certainty, management has determined that the Company's present capital resources will not be sufficient to fund its planned operations for at least one year from the issuance date of the financial statements which raises substantial doubt as to the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$3.84M
Shares
2.54M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$5000
-50%
FY2025
Net Income
-$4.18M
+10.8%
FY2025
Operating Margin
-84500%
-36380pp
FY2025
Diluted EPS
-$2.20
+24.7%
FY2025
Operating Cash Flow
-$2.87M
+42.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 | FY2006 | FY2005 | FY2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $3000 | $5000 | $10K | $5000 | $2.92M | $398K | $0 | — | $146K | $15.9M | $6.86M | — | — | — | $800K | $667K | — | — | — | — | — | — | — | |
| $1.65M | $1.36M | $362K | $16.28M | $25.02M | $49.64M | $52.7M | $38.33M | $34.13M | $45.08M | $157.79M | $106.79M | $32.71M | $42.85M | $83.45M | $57.08M | $12.91M | $4.56M | — | — | — | — | — | |
| $2.42M | $2.87M | $4.46M | $12.22M | $13.14M | $27.56M | $27.67M | $19.53M | $19.92M | $14.8M | $14.38M | $17.65M | $12.17M | $15.66M | $19.52M | $14.98M | $11.64M | $7.57M | — | — | — | $45K | $251K | |
| — | — | — | — | — | — | — | — | — | — | $290K | $357K | $462K | $738K | $658K | $268K | $188K | $330K | — | — | — | — | — | |
| — | — | $0 | $1.27M | $0 | — | — | — | — | — | — | — | — | $1.7M | — | — | — | — | — | — | — | — | — | |
| $4.06M | $4.23M | $4.82M | $34.27M | $38.03M | $77.95M | $80.36M | $57.86M | $54.05M | $59.88M | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| -$4.06M | -$4.23M | -$4.81M | -$34.27M | -$35.11M | -$77.55M | -$80.36M | -$57.86M | -$53.91M | -$53.49M | -$165.31M | -$120.1M | -$43.5M | -$57.71M | -$102.17M | -$71.4M | -$24.55M | -$12.12M | — | — | — | — | — | |
| — | -84500% | -48120% | -685340% | -1201.4% | -19484.67% | — | — | -36921.92% | -336.43% | -2409.37% | — | — | — | -12771.12% | -10704.65% | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | -$165.02M | -$119.74M | -$43.04M | -$56.98M | -$101.51M | -$71.13M | -$24.36M | -$11.79M | — | — | — | — | — | |
| — | — | $0 | $1.92M | $3.15M | $1.19M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| $48K | $49K | $133K | -$873K | -$2.63M | -$1.2M | $385K | $813K | $631K | $465K | $134K | $12K | -$5000 | -$579K | -$13K | $39K | $765K | $13K | — | — | — | — | — | |
| — | $0 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| -$4.01M | -$4.18M | -$4.68M | -$4.68M | -$37.73M | -$78.75M | -$79.98M | -$117.8M | -$53.12M | -$54.32M | -$165.3M | -$120.09M | -$31.78M | -$57.11M | -$96.13M | -$63.78M | -$32.67M | -$7.65M | -$25.23M | -$26.61M | -$17.86M | -$9.52M | -$5.69M | |
| — | -83520% | -46790% | -93580% | -1291.24% | -19786.68% | — | — | -36381.51% | -341.65% | -2409.23% | — | — | — | -12016.5% | -9561.92% | — | — | — | — | — | — | — | |
| -$4.29M | -$4.28M | -$4.68M | — | — | -$78.75M | -$79.98M | -$117.8M | $137.25M | -$73.26M | -$172.42M | -$120.09M | -$31.78M | — | — | — | — | — | — | — | — | — | — | |
| USD/shares | -$1.90 | -$2.20 | -$2.92 | -$21.97 | -$26.10 | -$55.50 | -$57.00 | -$105.00 | $144.00 | -$79.50 | -$198.00 | — | — | — | — | — | — | — | — | — | — | — | — |
| USD/shares | -$1.90 | -$2.20 | -$2.92 | -$21.97 | -$26.10 | -$55.50 | -$57.00 | -$105.00 | $144.00 | -$79.50 | -$198.00 | — | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | 1.95M | 1.6M | 1.6M | 1.45M | 1.43M | 1.4M | 1.12M | 956.72K | 912.92K | 869.28K | 836.11K | 674.2K | 572.95K | 523.64K | 440.03K | 306.69K | — | — | — | — | — | — |
| shares | — | 1.95M | 1.6M | 1.6M | 1.45M | 1.43M | 1.4M | 1.12M | 958.07K | 912.92K | 869.28K | 836.11K | 674.2K | 572.95K | 523.64K | 440.03K | 306.69K | — | — | — | — | — | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2009–FY2023: $6.27M in buybacks.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 2.06×
EV/EBIT
—
P/E (TTM)
—
Peer medians compare against the 150 similar-size Biotechnology companies (of 534 listed).